阿奇霉素与头孢类药物治疗慢性阻塞性肺疾病急性加重期效果分析.docVIP

阿奇霉素与头孢类药物治疗慢性阻塞性肺疾病急性加重期效果分析 　　摘要：目的 研究阿奇霉素与头孢类药物在慢性阻塞性肺疾病急性加重期中的应用价值。方法 以2015年4月～2017年3月本科门诊接诊的76例慢性阻塞性肺疾病急性加重期患者为研究对象，根据治疗方案对76例入选者进行分组：实验组中的38例患者采取阿奇霉素+头孢类药物治疗方案，对照组中的38例患者采取头孢类药物治疗方案。观察两组用药后不良反应的发生情况及临床疗效，并对其作出比较。结果 实验组的不良反应发生率为2.63%，和对照组的18.42%比较明显降低，组间差异显著（P0.05）。实验组治疗的总有效率为97.37%，比对照组的65.79%显著升高，组间差异明显（P0.05）。结论 慢性阻塞性肺疾病急性加重期合理联用阿奇霉素与头孢类药物，可减轻药物副作用，提高患者病情控制的效果。 　　关键词：阿奇霉素；慢性阻塞性肺疾病；头孢类药物 　　中图分类号：R563.9 文献标识码：A 文章编号：1006-1959（2017）18-0089-02 　　Abstract：Objective To study the value of azithromycin and cephalosporins in acute exacerbation of chronic obstructive pulmonary disease.Methods A total of 76 patients with acute exacerbation of chronic obstructive pulmonary disease were enrolled in the outpatient clinic from April 2015 to March 2017，and 76 patients were divided into groups according to the treatment plan：38 patients in the experimental group received azithromycin+ cephalosporins treatment program，the control group of 38 patients with cephalosporins treatment program.To observe the incidence of adverse reactions and the clinical efficacy of the two groups after treatment，and to compare them.Results The incidence of adverse reactions in the experimental group was 2.63%，which was significantly lower than that in the control group 18.42%，significant differences between the groups（P0.05）.In experimental group，the total effective rate was 97.37%，significantly higher than the control group 65.79%，with obvious difference between groups（P0.05）. Conclusion The rational use of azithromycin and cephalosporins in the acute exacerbation of chronic obstructive pulmonary disease can reduce the side effects of drugs and improve the effect of disease control. 　　Key words：Azithromycin；Chronic obstructive pulmonary disease；Cephalosporins 　　呼吸系统病理性改变是阻塞性肺疾病的一个重要病理特征，可对患者的身体机能造成较大的损伤[1]。而对于急性加重期患者来说，因其咳嗽与咳痰症状明显加重[2]，所以需及时接受对症治疗，以帮助其抑制病情进展，改善生活质量。一直以来，对于慢性阻塞性肺疾病急性加重期患者来说，我国临床常采取止咳化痰等常规治疗方案对其病情进行干预，但效果不佳，药物不良反应多，严重影响患者的预后[3]。对此，我们还应积极为本患者者寻找一种更安全、有效的治疗方案。此次研究，笔者将重点分析阿奇霉素